Cormedix Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Cormedix Inc's ROI in the third quarter of 2026?
Cormedix Inc recorded a cumulative net loss of $-114 million during 12 months ending in the third quarter of 2026, resulting in a negative return on investment (ROI) of -16.49%.

Within the Healthcare sector 174 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2026 from 2880 to 2955.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Investment Change TTM	181.92 %	550.06 %	774.74 %	570.57 %	278.47 %
Y / Y Net Income Change TTM	-	-44.21 %	-	-	-
Investment (TTM) in Millions	710	717	690	652	617
Return On Investment (TTM)	-16.49 %	1.36 %	-6.56 %	-15.47 %	56.64 %
CRMD's Overall Ranking	# 2955	# 2880	# 89	#	#
Seq. Investment Change TTM	3.48 %	22.74 %	38.42 %	60.35 %	138.62 %
Seq. Net Income Change TTM	-	-	-	-	749.9 %
Net Income (TTM) in Millions	-114	9	-36	-61	139

CRMD Company Profile >> Back to CRMD Roi Comparisons >> See Annual CRMD Return On Investment

Return On Investment CRMD's Ranking
Within:	No.
Industry	# 59
Sector	# 175
Overall	# 2955

Return On Investment Statistics
High	Average	Low
56.64 %	-450.14 %	-2004.93 %
(Sep 30 2025)		(Sep 30 2018)

News about Cormedix Inc Return on Investment ROI

DefenCath: Pioneering the Fight Against Life-Threatening Infections

January 8, 2024

CorMedix Inc. Sets the Stage for Life-Saving Breakthrough with Commercial and Operational Updates
Berkeley Heights, N.J., Jan. 08, 2024 - CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company dedicated to developing and commercializing therapeutic products for preventing and treating life-threatening diseases and conditions, has recently divulged a series of commercial and operational updates that are poised to revolutionize the healthcare landscape. With the highly anticipated launch of their groundbreaking product, DefenCath, CorMedix Inc. is charting a new course in the fight against life-threatening infections.
DefenCath, CorMedix s flagship product, is a cutting-edge therapeutic catheter lock solution that aims to prevent catheter-related bloodstream infections (CRBSIs) in patients requiring hemodialysis. This devastating condition affects thousands of individuals worldwide, leading to severe illnesses and even death. By introducing DefenCath, CorMedix Inc. hopes to transform the way this life-threatening disease is managed, ultimately saving countless lives and decreasing healthcare costs.
The commercial and operational updates announced by CorMedix Inc. illustrate the company s commitment to not only bringing DefenCath to market but also driving its success once it becomes available. The updates include key strategic partnerships, enhanced manufacturing capabilities, and crucial regulatory approvals that will propel DefenCath into the forefront of the medical field.

Financial Statements
Cormedix Inc's III. Quarter Investments	$ 710 Millions	CRMD's Balance sheet
Cormedix Inc's III. Quarter Income	$ -15 Millions	Quarterly CRMD's Income Statement
CRMD's Income by Division		See CRMD's Income by Division

CRMD Annual Return On Investment	(Mar 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	115	85	71	56	64
Y / Y Investment Growth	35.51 %	20.3 %	26.79 %	-12.38 %	40.88 %
Net Income in Millions	21	-18	-46	-30	-28
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	17.92 %	-21.09 %	-65.58 %	-53.3 %	-44.36 %

Annual Roi Comment

In the fiscal year 2025 ROI improved to 17.92 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
CRMD's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for CRMD's Competitors
Subscribers only: Roi for Cormedix Inc's Suppliers
Subscribers only: Return On Investment for CRMD's Customers

Other Ratios
CRMD's Roa	CRMD's Inventory Turnover Ratio	CRMD's Growth Rates	CRMD's Dividend Statistics
	CRMD's Profitability Ratios	CRMD's Asset Turnover Ratio	CRMD's Dividend Growth
CRMD's Roe	CRMD's Valuation Ratios	CRMD's Financial Strength Ratios	CRMD's Dividend Payout Ratio

Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector

ROI

Date modified: 2026-11-13T11:57:20+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.